Edwin M. Posadas, MD

home / authors / edwin-m-posadas-md

Articles

Plasma Glutamine as a Prognostic Biomarker in Localized Prostate Cancer: Comparison of Conventional Variables in Risk Stratification

Bethany Smith, PhD;Sungjin Kim, MS ;Mourad Tighiouart, PhD;Edwin M. Posadas, MD;Leland Chung, PhD;Robert A. Figlin, MD;Neil Bhowmick, PhD;Jun Gong, MD

September 14th 2021

This study investigated the biomarker potential of glutamine among known prognostic variables in localized prostate cancer.

Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics

Jun Gong, MD;Edwin M. Posadas, MD;Neil Bhowmick, PhD;Hyung L. Kim, MD;Timothy J. Daskivich, MD;Amit Gupta, MD;Howard M. Sandler, MD;Mitchell Kamrava, MD;Zachary S. Zumsteg, MD;Stephen J. Freedland, MD;Robert A. Figlin, MD

March 17th 2021

Experts in the field review integration of approved PARP inhibitors into advanced prostate cancer clinical practice.

Third-Line Treatment Options for Kidney Cancer

Edwin M. Posadas, MD;Suwicha Limvorasak, PharmD;Robert A. Figlin, MD

September 15th 2016

Effectively, the field has tested agents for metastatic disease in only two clinical settings: primary management of metastatic disease (first-line) and after progression with a first-line therapy (second-line); however, there are no category 1 data that support the use of any agent in the third-line setting.